SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

SPY is trending due to significant market volatility triggered by conflicting reports regarding a potential wind-down of the U.S. conflict with Iran, prompting intense community debate over whether this signals a genuine de-escalation or a tactical market pump. Traders are actively discussing the impact of these geopolitical headlines on energy costs, the potential for a short squeeze following recent sell-offs, and skepticism toward anonymous sources fueling overnight price swings.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing significant downward pressure as investors weigh potential memory sector headwinds, including AI efficiency developments, alongside broader market anxiety surrounding geopolitical tensions. The community is actively debating whether this pullback represents a fundamental shift in the cyclical demand for memory chips or a tactical entry point for long-term investors following recent earnings strength.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is facing significant market volatility and community debate as investors weigh the potential impact of the pending Clarity Act against macroeconomic pressures and ongoing token supply concerns. While some traders are aggressively accumulating on dips, citing long-term institutional adoption and integration potential, others are increasingly frustrated by persistent price stagnation and the frequent dilution from scheduled supply unlocks.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing heightened volatility and intense social media debate, driven by skepticism over its ongoing Bitcoin treasury strategy and concerns about the dilutive impact of capital raises. While some traders continue to capitalize on the stock's high-beta sensitivity to Bitcoin price action, others are actively betting against the company, citing long-term sustainability risks and the aggressive issuance of equity and debt.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is currently a focal point for investors as they navigate high volatility and institutional positioning ahead of upcoming Medicare Advantage rate announcements. The community is sharply divided, with some betting on a major bounce and institutional accumulation while others remain skeptical due to ongoing regulatory scrutiny and persistent macroeconomic headwinds.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Kennedy Space Center, FL.

Starfighters Space Inc

Starfighters Space is trending due to heightened community speculation surrounding a potential SpaceX IPO and the company's recent operational updates, including a strategic partnership with Mu-G Technologies for microgravity missions. While bulls highlight the stock's low float and potential for a short squeeze alongside broader space sector growth, bears remain skeptical, citing leadership turnover and a lack of revenue as significant red flags.

Invesco QQQ Trust Series 1 - Units of beneficial interest

Market participants are reacting to conflicting signals regarding the conflict in Iran, with sentiment being driven by speculative headlines about potential de-escalation versus fears of a prolonged energy crisis. The community is actively debating the reliability of these news sources, with many expressing skepticism about the sustainability of overnight rallies and remain focused on how geopolitical tensions and oil price volatility will impact broader equity trends.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as shareholders weigh a cryptic message from CEO Dr. Patrick Soon-Shiong about "strengthening the balance sheet" and "recharging for global expansion," which has sparked intense debate over whether it signals non-dilutive funding or future share dilution. The community is actively discussing the potential for international partnerships, particularly in the Middle East and Europe, while expressing frustration over ongoing short-seller activity and legal challenges.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is capturing significant market attention as a unique, permissionless brand driven by an unusually active community that focuses on real-world utility and product development rather than standard crypto hype. Enthusiasts are actively rallying behind its various grassroots initiatives, including apparel, food products, and lifestyle events, which they argue distinguishes the project from typical short-term speculative assets.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is facing downward pressure amid broader market volatility and geopolitical uncertainty, though institutional investors continue to accumulate the asset for long-term positioning. Community sentiment remains polarized, with many traders debating whether recent price action represents a buying opportunity or the start of a deeper cyclical downturn.

statis crypto Watchlist

Bitcoin

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Healthcare ETFs in Spotlight Amid Eli Lily's $2.8B AI Drug Move

Eli Lilly's $2.75B AI drug deal with Insilico spotlights healthcare ETFs as investors seek diversified exposure to the fast-growing AI-driven pharma space. 

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

U.S. Food and Drug Administration vaccine chief Vinay Prasad is reportedly leaving the agency at the end of April.The Wall Street Journal <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/fdas-controversial-vaccines-chief-will-leave-the-agency-7fe59aa3">reported</a> the upcoming departure on Friday, citing FDA Commissioner Marty Makary.Shares of select pharmaceutical companies with whom Prasad has sparred with during his tenure rallied on the news. Shares of Moderna (<a href="https://stocktwits.com/symbol/MRNA">MRNA</a>) traded 3% higher after hours while uniQure (<a href="https://stocktwits.com/symbol/QURE">QURE</a>) stock rallied 50%. Shares of Sarepta Therapeutics (<a href="https://stocktwits.com/symbol/SRPT">SRPT</a>) also gained 5% in extended hours of trading.Makary said that federal health officials are now on the lookout for a replacement for Prasad who led the Center for Biologics Evaluation and Research (CBER) at the FDA. He was responsible for reviewing certain cancer drugs, gene therapies, and other treatments in addition to vaccines.<h2 class="st-heading-2">Prasad’s Shaky Tenure</h2>During his tenure, Prasad faced several disputes pertaining to drug reviews.Earlier this year, Prasad refused to consider an application seeking approval for Moderna’s flu shot but the agency later <a href="https://stocktwits.com/news-articles/markets/equity/moderna-stock-fda-accepts-revised-flu-vaccine-application-for-review/cZR0MwoR4v1">pivoted</a> after Moderna agreed on another confirmation study post-approval.Most recently, the FDA has gone up against uniQure’s gene therapy for ⁠Huntington's disease. The agency has <a href="https://stocktwits.com/news-articles/markets/equity/why-did-qure-stock-almost-halve-pre-market-today/cZd344CRIcD">recommended</a> that the company conduct a sham-surgery-controlled study after disagreeing with other study data submitted.Prasad previously <a href="https://stocktwits.com/news-articles/markets/equity/fda-official-who-halted-sarepta-s-gene-therapy-resigns-amid-backlash-over-access-to-duchenne-treatment/choQYmjR5yz">resigned</a> in July 2025 merely months into the job following controversies over decisions on Sarepta Therapeutics’ Elevidys gene therapy for Duchenne muscular dystrophy. Prasad was brought back shortly afterwards.<h2 class="st-heading-2">Reasons For Exit</h2>Regarding Prasad’s departure this term, Makary reportedly said that he had only intended to remain at the agency during his period of absence at the University of California.As per the agency commissioner, all policies that Prasad wanted to help implement have now been announced, including a new priority program to expedite the application review process for treatments that meet national priorities.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/incyte-drug-approved-in-europe-for-treating-yet-another-rare-cancer/cZdLgTHRI49">Incyte’s Drug Approved In Europe For Treating Yet Another Rare Cancer</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

QURE, SRPT, MRNA Shares Rally On Report Of Vinay Prasad’s FDA Exit

The Wall Street Journal reported the upcoming departure on Friday, citing FDA Commissioner Marty Makary.

Equity

The Wall Street Journal reported the upcoming departure on Friday, citing FDA Commissioner Marty Makary.


TBPH Stock Slumps 30%, Falls Below 200-DMA For First Time In Over 9 Months As Phase 3 Study Misses Primary Endpoint

TBPH company reported that its Phase 3 CYPRESS study of ampreloxetine in patients with hypotension failed to meet its primary endpoint.

The company reported that its Phase 3 CYPRESS study of ampreloxetine in patients with hypotension failed to meet its primary endpoint.

<ul class="summary-bullets"><li>Makary urged the Trump administration to partner with the pharmaceutical industry.&nbsp;</li><li>The senior official is of the opinion that there exists multiple bottlenecks that have caused the U.S. to lag behind.&nbsp;</li><li>As per CNBC, China now conducts more clinical trials than the U.S. and accounts for nearly a third of new global drug approvals.</li></ul>The U.S. Food and Drug Administration (FDA) Commissioner Marty Makary on Wednesday reportedly warned that the country is falling behind its Asian rival China in drug development.Makary, in an <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2026/02/18/fda-chief-warns-us-is-losing-ground-to-china-in-early-drug-trials.html">interview</a> with CNBC, further called for reforms that could streamline the process for starting trials on new treatments.The senior official is of the opinion that there exists multiple bottlenecks that have caused the U.S. to lag behind. Makary recommended that the Trump administration partner with the pharmaceutical industry “to help them deliver more cures and meaningful treatments for the American public.”As per CNBC, China now conducts more clinical trials than the U.S. and accounts for nearly a third of new global drug approvals.<h2 class="st-heading-2">FDA’s Efforts</h2>Last year, the FDA initiated a program called the Commissioner's National Priority Voucher program in a bid to expedite the review of certain drug applications. The program aims to reduce FDA assessment time to one to two months from the standard 10 to 12 months.So far, over 15 drugs from various pharma companies have been awarded the voucher and while one has been approved, another has also been rejected.Earlier this month, FDA refused to approve Disc Medicine’s bitopertin oral tablets for the treatment of Erythropoietic Protoporphyria despite tapping the drug for fast review.However, the agency approved Augmentin XR manufactured by USAntibiotics in December after granting it the voucher. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/IHE"> iShares U.S. Pharmaceuticals ETF</a> (IHE) stayed within the ‘neutral’ territory coupled with ‘normal’ message volume.The ETF closed marginally in the red on Wednesday but has gained about 29% over the past 12 months.Meanwhile, Invesco Pharmaceuticals ETF (PJP) and State Street SPDR S&amp;P Pharmaceuticals ETF (XPH) added 26% and 27%, respectively.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/carvana-dismisses-short-seller-allegations-as-misleading/cZRK3kWR4wG">Carvana Dismisses Short Seller Allegations As Misleading: Retailer’s Q4 Earnings Disappoint Wall Street</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

FDA Commissioner Marty Makary speaks at a news conference on removing synthetic dyes from America's food supply, at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. (Photo by Nathan Posner/Anadolu via Getty Images)

FDA Commissioner Raises Concerns About US Pharma Lagging Behind China In Drug Development

Marty Makary, in an interview with CNBC, further called for reforms that could streamline the process for starting trials on new treatments.

<ul class="summary-bullets"><li>The company’s FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S.&nbsp;</li><li>With this step, ART100 moves from regulatory clearance to active commercial availability, the company said.</li><li>Earlier, Inspira announced a non-binding term sheet for a proposed two-part deal to acquire an advanced liquid biopsy diagnostics business</li></ul>Shares of Inspira Technologies OXY (IINN) popped over 28% in pre-market trading on Monday after Israel’s largest health services provider approved the procurement of its FDA-cleared ART100 platform.<a href="https://stocktwits.com/symbol/IINN">IINN shares</a> gave up premarket gains and fell around 3% after the opening bell.&nbsp;The company secured approval from Clalit Health Services’ Medical Equipment Committee, allowing its INSPIRA ART100 system to be immediately procured and deployed across a healthcare network serving roughly 4.9 million members.<h2 class="st-heading-2">ART100 Regulatory Clearance</h2>With this step, ART100 moves from regulatory clearance to active commercial availability, marking a significant growth opportunity for Inspira and strong clinical validation.“By securing this approval, we are laying the foundation for potentially long-term, high-quality revenue. This validation from a world-class, data-driven health ecosystem serves as a powerful reference case as we accelerate our commercialization efforts in the U.S. and other global markets,” said Dagi Ben-Noon, CEO of Inspira Technologies.The company’s FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and for (Extracorporeal Membrane Oxygenation) ECMO procedures outside the U.S.<h2 class="st-heading-2">Top U.S. Medical Center Clears ART100&nbsp;</h2>In January, Inspira Technologies’ ART100 system completed clinical evaluation at a top U.S. academic medical centre and moved into the budgeted procurement stage. The system successfully treated about 30 patients across surgeries, transplants, and other critical procedures, leading to its adoption into routine clinical workflows.&nbsp;With the evaluation phase now closed, the hospital has begun an internal process to purchase multiple ART100 units, pending final budget approval.Earlier, Inspira announced a non-binding term sheet for a proposed two-part deal to acquire an advanced liquid biopsy diagnostics business. The transaction also includes a planned $15 million strategic equity investment.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.The stock has shed around 25% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

Why Did IINN Stock Surge 28% In Pre-Market Today?

The company won approval from Clalit Health Services to deploy its INSPIRA ART100 system across a network of around 4.9 million members.

<ul class="summary-bullets"><li>Hims &amp; Hers said the compounded copy uses the same active ingredient as Wegovy but features a different formulation and delivery system.</li><li>The compounded pill will start at the introductory pricing for the first month for qualifying new customers under a five-month plan.</li><li>The pill is engineered to preserve the active ingredient during digestion and improve absorption.</li></ul>Shares of Hims &amp; Hers Health, Inc. (HIMS) rose 10% on Thursday after the company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month.Hims &amp; Hers said the compounded copy uses the same active ingredient as Wegovy but features a different formulation and delivery system from the FDA-approved oral semaglutide. Novo Nordisk originally introduced Wegovy as a once-weekly injection and expanded the franchise earlier this year with the launch of an oral pill version.<h2 class="st-heading-2">$100 Cheaper Than Novo’s Wegovy</h2>Hims &amp; Hers said treatment plans using the compounded pill will start at an introductory $49 for the first month for qualifying new customers under a five-month plan. The remaining months are priced at $99 per month, payable in advance.According to Novo Nordisk’s website, Wegovy pills are priced at $149 per month for a 1.5 mg dose.Hims &amp; Hers stated that its compounded pill is engineered to preserve the active ingredient during digestion and improve absorption, offering an alternative for patients who want to avoid injections.Meanwhile, NVO shares fell nearly 6%.<h2 class="st-heading-2">Novo’s Pricing Challenges</h2>Earlier this week, Novo said it expects adjusted sales for full year 2026 to drop between 5% and 13%, with operating profit potentially falling by 13% due to pricing pressure, intensifying competition, and upcoming patent expiries for key ingredients in Wegovy and Ozempic in select markets outside the U.S.“Our 2026 guidance reflects a year of unprecedented pricing pressure,” CEO Mike Doustdar said in a call with journalists on Wednesday. Doustdar added that Novo would have to accept short-term pain to lift volumes, arguing that lowering prices would pay off in the long-run.The pill variant has already seen significant traction since its launch in January.“I can tell you, as of this week, we have over 170,000 people that are on the Wegovy pill, and most of that is self-pay,” Doustdar said in a call with analysts.Eli Lilly (LLY), the maker of weight-loss drugs Mounjaro and Zepbound, saw its shares fall 6.5%.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/HIMS">HIMS</a> on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, while chatter was ‘extremely high’ on the platform.One user saw the new launch as a “trend changing event.”<stembedurl>https://stocktwits.com/Dr_Stoxx/message/644091407</stembedurl>Another bullish user highlighted HIM’s latest developments.<stembedurl>https://stocktwits.com/tothebulltothewall/message/644092695</stembedurl>Year-to-date, the stock has declined around 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-b-stock-is-falling-despite-q4-beat/cZbZB3uR4VV">Barrick’s Q4 Earnings Beat Expectations – So, What Is Dragging The Stock Down In Premarket Today?</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Hims & Hers Health in front of a screen showing the company's stock market chart. (Photo illustration by Cheng Xin/Getty Images)

HIMS New $49 Pill Lifts Stock 10%, But Why Are NVO, LLY Stocks Falling?

The company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month.

HIMS Stock Rises On Low-Cost Wegovy Alternative, Raising New Pricing Questions For Novo And Lilly

The company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month.



<ul class="summary-bullets"><li>Eli Lilly issued a revenue guidance between $80 billion and $83 billion for fiscal 2026</li><li>For the full year 2025, Eli Lilly’s revenue grew 45% to $65.18 billion.</li><li>CFO Lucas Montarce said the company expects to launch the multidose Zepbound within the next 30 days, according to a Bloomberg report.</li></ul>Shares of Eli Lilly (LLY) jumped 8% in pre-market trading on Wednesday, after the company reported better-than-expected fourth-quarter results and issued a revenue guidance between $80 billion and $83 billion for fiscal 2026, significantly above fiscal 2025 revenue.<a href="https://stocktwits.com/symbol/LLY">LLY shares</a> were up 9.2% after the opening bell.Fourth-quarter revenue surged 43% to $19.3 billion, driven by volume growth from Mounjaro and Zepbound – signalling sustained momentum in its obesity and diabetes portfolio. Analysts had expected a revenue of $17.86 billion, according to Fiscal.ai data. Meanwhile, Q4 earnings increased by 51% to $7.39 per share on a reported basis, compared to Street estimates of $7.22 per share.For the full year, Eli Lilly’s revenue grew 45% to $65.18 billion. LLY expects earnings of $33.50 to $35 per share for full-year 2026.<h2 class="st-heading-2">Mounjaro And Zepbound Drive Revenue Growth</h2>Global revenue for Mounjaro surged 110% to $7.4 billion in Q4 2025, with U.S. sales rising 57% to $4.1 billion on strong demand despite lower realized prices. International revenue jumped to $3.3 billion from $899 million a year earlier, driven mainly by volume growth.U.S. Zepbound revenue climbed 122% to $4.2 billion, fueled by higher demand but partially offset by pricing pressure. Meanwhile, revenue from Verzenio, Eli Lilly’s drug to treat metastatic breast cancer, edged up 3% to $1.6 billion.<h2 class="st-heading-2">Eli Lilly’s Product Pipeline</h2>After the FDA authorized Lilly to market Zepbound in a multidose device last month, CFO Lucas Montarce said the company expects to launch the multidose pen within the next 30 days, according to a report by Bloomberg on Wednesday.In an interview with CNBC last month, CEO Dave Ricks said the upcoming Medicare coverage for obesity drugs could significantly boost the launch of its experimental weight-loss pill, Orforglipron. Ricks added that the company expects Medicare coverage to begin immediately after the drug’s launch.<h2 class="st-heading-2">LLY Pulls Ahead As NOVO Faces Headwinds</h2>Eli Lilly’s optimistic outlook stands in stark contrast to Novo Nordisk (NVO), which expects adjusted sales to decline between 5% and 13% and operating profit to drop by up to 13%. The company cited pricing pressure, intensifying competition, and upcoming patent expiries for the key ingredients in Wegovy and Ozempic in select markets outside the U.S.“This is just more evidence they are dominating the category,” Mizuho’s Jared Holz told Bloomberg of Eli Lilly’s obesity market position. “Novo is playing from behind and everyone knows it.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘bearish’ over the past 24 hours, amid ‘high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/LLY_jpg_1dcca688cf.webp" alt="LLY.jpg" width="933" height="102"><figcaption>LLY's Sentiment Meter and Message Volumes on Feb. 4, 2026 | Source: Stocktwits</figcaption></figure>One user said that Lilly proved that with “a good product comes great demand.”<stembedurl>https://stocktwits.com/Bagholding_VKTX/message/643931351</stembedurl>LLY shares have gained around 25% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-fda-higher-dose-wegovy-nvo-stock-outlook/cZbjThlR4ZM">Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

LLY Stock Surges On Q4  Beat – Obesity, Diabetes Drugs Drive Strong FY26 Outlook

LLY Stock - Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.

Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.

<ul class="summary-bullets"><li>Kazia stated that in murine triple-negative breast cancer preclinical models, NDL2 reduced primary tumor volume by 49% as monotherapy.</li><li>In combination with the anti-PD-1 therapy, the treatment reduced the volume of the primary tumor by 73%.</li><li>In patients with lung metastases, Kazia stated that NDL2, combined with anti-PD-1 therapy, reduced the primary tumor’s volume by 50%.</li></ul>Kazia Therapeutics Inc.’s (KZIA) shares rose more than 6% in Friday’s pre-market trade after the company announced new preclinical and translational data for NDL2, a protein degrader.The Sydney, Australia-based oncology-focused pharmaceutical company stated that across multiple preclinical models and patient-derived samples, NDL2 demonstrated reversal of immune exhaustion, suppression of metastatic biology, and enhanced anti-tumor activity. This includes the combination of NDL2 with anti-PD-1 therapy, which uses monoclonal bodies such as nivolumab or pembrolizumab to block the PD-1 protein on T-cells.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/KZIA">Kazia Therapeutics</a> was in the ‘bullish’ territory at the time of writing, while message volume was at ‘high’ levels.<h2 class="st-heading-2">Highlights Of New NDL2 Data</h2>Kazia stated that in murine triple-negative breast cancer (TNBC) preclinical models, NDL2 reduced primary tumor volume by 49% as monotherapy. In combination with the anti-PD-1 therapy, the treatment reduced the volume of the primary tumor by 73%.In patients with lung metastases, Kazia stated that NDL2, combined with anti-PD-1 therapy, reduced the primary tumor’s volume by 50%.The company added that no toxicity or hemolysis was observed, while noting that the immune checkpoint function at the cell surface was preserved, and the plasma stability was favorable.<h2 class="st-heading-2">What Is NDL2 Aimed At?</h2>Kazia is currently developing the NDL2 protein degrader to selectively eliminate nuclear PD-L1 (Programmed Death-Ligand 1).PD-L1 is a protein found on the surface of many cancer cells as well as some normal cells. The protein helps these cells evade the immune system.<a href="https://stocktwits.com/symbol/KZIA">KZIA stock</a> is down 6% year-to-date and 12% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sofi-stock-rises-after-sofi-technologies-reports-1b-quarterly-revenue-first-time/cmySKHPR4ST">SOFI Stock Rises Pre-Market After SoFi Technologies Reports $1B Quarterly Revenue For The First Time</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

KZIA Stock Is Rising Today — What Does Its Data For Nuclear PD-L1 Degrader Show?

Kazia stated that across multiple preclinical models and patient-derived samples, NDL2 demonstrated reversal of immune exhaustion, suppression of metastatic biology, and enhanced anti-tumor activity.

3 Healthcare ETFs to Buy as Flat Medicare Rate Proposal Hits Insurers

Flat Medicare Advantage rate hikes hit insurers hard, but diversified healthcare ETFs may help investors weather the policy shock. 

iShares Trust - iShares U.S. Pharmaceuticals ETF

Patrick OShaughnessy - @patrick_oshag on X

Citrini - @Citrini7 on X

Bucco Capital - @buccocapital on X

Joe Weisenthal - @TheStalwart on X

The must-watch individual or show that brings entertainment to finance. This award celebrates the content you look forward to daily - bringing a sharp market edge to engaging discussions. 

IHE
iShares U.S. Pharmaceuticals ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IHE News

IHEiShares U.S. Pharmaceuticals ETF